KR970059161A - O-데메틸트라마돌 에난티오머의 제조방법 - Google Patents

O-데메틸트라마돌 에난티오머의 제조방법 Download PDF

Info

Publication number
KR970059161A
KR970059161A KR1019970001204A KR19970001204A KR970059161A KR 970059161 A KR970059161 A KR 970059161A KR 1019970001204 A KR1019970001204 A KR 1019970001204A KR 19970001204 A KR19970001204 A KR 19970001204A KR 970059161 A KR970059161 A KR 970059161A
Authority
KR
South Korea
Prior art keywords
enantiomer
base
tramadol
demethyltramadol
converted
Prior art date
Application number
KR1019970001204A
Other languages
English (en)
Other versions
KR100507396B1 (ko
Inventor
이파르스 그라우둠스
페터 얀젠
볼프강 베르너 알프레드 슈트라쓰부르거
엘마 요제프 프리데리히스
헬무트 부슈만
베르너 빈터
Original Assignee
비르츠 프란츠, 파우쓰-베르구스
그뤼넨탈 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비르츠 프란츠, 파우쓰-베르구스, 그뤼넨탈 게엠베하 filed Critical 비르츠 프란츠, 파우쓰-베르구스
Publication of KR970059161A publication Critical patent/KR970059161A/ko
Application granted granted Critical
Publication of KR100507396B1 publication Critical patent/KR100507396B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

본 발명은 0-데메틸트라마돌의 에난티오머의 제조방법 및 진통제로서의 상기 에난티오머의 용도가 기술되어 있다.

Description

0-데메틸트라마돌 에난티오머의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 라세미 트라마돌염을 염기로 전환시키고, (-)-트라마동 에난티오머를 L-(+)-타르타르산으로 침전시켜 분리하고 방출시킨 후 염기를 디이소부틸알루미늄 하이드리드에 의해 0-데메틸트라마돌의 (+)-에난티오머로 전환시키고, 0-데메틸트라마돌의 (+)-에난티오머를 트라마돌 염기의 방출 및 디이소부틸알루미늄 하이드라이드와의 반응에 의해 타르타르산 침전물로부터 수득한 모액으로부터 제조함을 특징으로 하는 0-데메틸트라마돌 에난티오머의 제조방법.
  2. 제1항에 있어서, 라세미 트라마돌 하이드로 클로라이드를 사용하는 것을 특징으로 하는 방법.
  3. 제1항 또는 제2항에 있어서, L-(+)-타르타르산을 유기용매의 존재하에서, 바람직하게는 지방족 C1-5알코올의 존재하에서 사용하는 것을 특징으로 하는 방법.
  4. 제1항 내지 제3항 중 어느 한 항에 있어서, (-)-트라마돌 에난티오머를 결정화로 분리하는 것을 특징으로 하는 방법.
  5. 제1항 내지 제4항 중 어느 한 항에 있어서, 디이소부틸 알루미늄 하이드리드와의 반응에 앞서, 트라마돌 염기와 상응하는 에난티오머를 타르트레이트와는 상이한 염으로 전환시키고, 이어서 이로부터 염기를 방출시키는 것을 특징으로 하는 방법.
  6. 제5항에 있어서, 트라마돌 염기에 상응하는 에난티오머를 하이드로 클로라이드로 전환시키는 것을 특징으로 하는 방법.
  7. 약물중의 진통 활성 성분으로서의 라세메이트 또는 에난티오머 형태의 염기 및/또는 염으로서의 0-데메틸트라마돌 그 자체 또는 라세메이트 또는 에난티오머 형태의 염기 및/또는 염으로서의 트라마돌이 배합된 상기 0-데메틸트라마돌의 용도.
  8. 제7항에 있어서, 0-데메틸트라마들의 (+)-에난티오머가 사용하는 것을 특징으로 하는 용도
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970001204A 1996-01-19 1997-01-17 O-데메틸트라마돌에난티오머의제조방법 KR100507396B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19601744A DE19601744C2 (de) 1996-01-19 1996-01-19 Verfahren zur Herstellung der Enantiomeren von O-Demethyltramadol
DE19601744.0 1996-01-19

Publications (2)

Publication Number Publication Date
KR970059161A true KR970059161A (ko) 1997-08-12
KR100507396B1 KR100507396B1 (ko) 2005-12-20

Family

ID=7783111

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970001204A KR100507396B1 (ko) 1996-01-19 1997-01-17 O-데메틸트라마돌에난티오머의제조방법

Country Status (32)

Country Link
US (1) US5728885A (ko)
EP (1) EP0786450B1 (ko)
JP (1) JPH09216857A (ko)
KR (1) KR100507396B1 (ko)
CN (1) CN1073085C (ko)
AR (1) AR005390A1 (ko)
AT (1) ATE191454T1 (ko)
AU (1) AU705195B2 (ko)
BR (1) BR9700079A (ko)
CA (1) CA2195372C (ko)
CO (1) CO4520186A1 (ko)
CZ (1) CZ292427B6 (ko)
DE (2) DE19601744C2 (ko)
DK (1) DK0786450T3 (ko)
ES (1) ES2147341T3 (ko)
GR (1) GR3033390T3 (ko)
HK (1) HK1004810A1 (ko)
HU (1) HU223661B1 (ko)
IL (1) IL120029A (ko)
IN (1) IN181540B (ko)
MY (1) MY116593A (ko)
NO (1) NO306943B1 (ko)
NZ (1) NZ299998A (ko)
PE (1) PE29998A1 (ko)
PL (1) PL187373B1 (ko)
PT (1) PT786450E (ko)
RU (1) RU2185371C2 (ko)
SI (1) SI0786450T1 (ko)
SK (1) SK282629B6 (ko)
UA (1) UA45342C2 (ko)
UY (1) UY24438A1 (ko)
ZA (1) ZA97367B (ko)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19712398A1 (de) * 1997-03-25 1998-10-01 Gruenenthal Gmbh Orale Anwendung von (+)-0-Demethyltramadol als Schmerzmittel
PE20010623A1 (es) 1999-10-05 2001-07-07 Gruenenthal Chemie Uso de (+)-tramadol y/o o-demetiltramadol para tratamiento de urgencia urinaria incrementada y/o incontinencia urinaria
WO2001034125A2 (en) * 1999-11-09 2001-05-17 Darwin Discovery Limited Therapeutic use and formulation of (-)-tramadol
DE10049483A1 (de) 2000-09-29 2002-05-02 Gruenenthal Gmbh Substituierte 1-Aminobutan-3-ol-Derivate
DE10108123A1 (de) * 2001-02-21 2002-10-02 Gruenenthal Gmbh Wirkstoffkombination
DE10108122A1 (de) 2001-02-21 2002-10-02 Gruenenthal Gmbh Arzneimittel auf Basis von Tramadol
DE10109763A1 (de) * 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
US20050176790A1 (en) 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
US6974839B2 (en) 2001-03-16 2005-12-13 Dmi Biosciences, Inc. Method of delaying ejaculation
US6649783B2 (en) * 2001-10-03 2003-11-18 Euro-Celtique, S.A. Synthesis of (+/-)-2-((dimethylamino)methyl)-1-(aryl)cyclohexanols
AU2002364517A1 (en) 2001-11-30 2003-06-17 Sepracor Inc. Tramadol analogs and uses thereof
US20040248979A1 (en) * 2003-06-03 2004-12-09 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
DE102005033732B4 (de) * 2005-05-27 2014-02-13 Grünenthal GmbH Trennung stereoisomerer N,N-Dialkylamino-2-alkyl-3-hydroxy-3-phenyl-alkane
EP1785412A1 (en) * 2005-11-14 2007-05-16 IPCA Laboratories Limited Tramadol recovery process
SG178775A1 (en) 2007-02-12 2012-03-29 Dmi Biosciences Inc Reducing side effects of tramadol
MX2009008491A (es) 2007-02-12 2010-01-20 Dmi Biosciences Inc Tratamiento de disfuncion erectil y eyaculacion prematura copatologicas.
US20110251286A1 (en) * 2010-03-10 2011-10-13 Gruenenthal Gmbh Crystalline salts and/or co-crystals of O-desmethyltramadol
EP2383255A1 (en) 2010-04-28 2011-11-02 Lacer, S.A. New compounds, synthesis and use thereof in the treatment of pain
EP2530072A1 (en) 2011-06-03 2012-12-05 Lacer, S.A. New compounds, synthesis and use thereof in the treatment of pain
US10702485B2 (en) 2011-07-09 2020-07-07 Syntrix Biosystems Inc. Compositions and methods for overcoming resistance to tramadol
US10781163B2 (en) 2017-09-18 2020-09-22 R L Finechem Private Limited Process for preparation of O-Desmethyltramadol and salts thereof
US11000488B2 (en) 2019-03-22 2021-05-11 Syntrix Biosystems Inc. Treating pain using desmetramadol
CN118108610A (zh) * 2024-04-30 2024-05-31 山东新华制药股份有限公司 盐酸去甲曲马多的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1518663A1 (de) * 1965-08-02 1969-12-18 Gruenenthal Chemie Basisch substituierte Cycloalken-derivate und Verfahren zu ihrer Herstellung
US3652589A (en) * 1967-07-27 1972-03-28 Gruenenthal Chemie 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
EP0534628B1 (en) * 1991-09-06 1996-11-20 Mcneilab, Inc. Compositions comprising a tramadol material and any of codeine, oxycodone or hydrocodone, and their use
KR100243956B1 (ko) 1991-09-06 2000-03-02 랄프 알. 팔로 트라마돌 물질 및 아세트아미노펜을 포함하는 통증 치료용 약제학적 조성물
JPH06122686A (ja) * 1992-10-12 1994-05-06 Fujisawa Pharmaceut Co Ltd ラセミ体の光学分割法

Also Published As

Publication number Publication date
HU223661B1 (hu) 2004-11-29
MY116593A (en) 2004-02-28
US5728885A (en) 1998-03-17
CN1167107A (zh) 1997-12-10
DK0786450T3 (da) 2000-07-10
ES2147341T3 (es) 2000-09-01
NZ299998A (en) 1998-01-26
PL187373B1 (pl) 2004-06-30
BR9700079A (pt) 1998-11-10
UA45342C2 (uk) 2002-04-15
DE19601744A1 (de) 1997-07-31
CA2195372C (en) 2005-08-30
SI0786450T1 (en) 2000-08-31
AU705195B2 (en) 1999-05-20
DE19601744C2 (de) 1998-04-16
PT786450E (pt) 2000-08-31
EP0786450A3 (de) 1997-10-15
AU1221697A (en) 1997-07-24
GR3033390T3 (en) 2000-09-29
EP0786450A2 (de) 1997-07-30
IN181540B (ko) 1998-07-11
HK1004810A1 (en) 1998-12-11
UY24438A1 (es) 1997-01-10
CN1073085C (zh) 2001-10-17
SK282629B6 (sk) 2002-10-08
CO4520186A1 (es) 1997-10-15
CZ15797A3 (cs) 1998-05-13
SK6797A3 (en) 1997-08-06
RU2185371C2 (ru) 2002-07-20
ATE191454T1 (de) 2000-04-15
CZ292427B6 (cs) 2003-09-17
DE59604885D1 (de) 2000-05-11
EP0786450B1 (de) 2000-04-05
NO970212D0 (no) 1997-01-17
PL318002A1 (en) 1997-07-21
HUP9700140A2 (hu) 1998-01-28
CA2195372A1 (en) 1997-07-20
NO306943B1 (no) 2000-01-17
AR005390A1 (es) 1999-04-28
IL120029A (en) 2000-01-31
MX9700523A (es) 1997-07-31
ZA97367B (en) 1997-07-17
PE29998A1 (es) 1998-08-08
HUP9700140A3 (en) 2000-03-28
HU9700140D0 (en) 1997-03-28
KR100507396B1 (ko) 2005-12-20
NO970212L (no) 1997-07-21
JPH09216857A (ja) 1997-08-19
IL120029A0 (en) 1997-04-15

Similar Documents

Publication Publication Date Title
KR970059161A (ko) O-데메틸트라마돌 에난티오머의 제조방법
RU97100984A (ru) Способ получения энантиомеров o-диметилтрамадола
IL255433B2 (en) (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
EP2343275A3 (fr) Procédé de préparation et forme cristalline I des énantiomères optiques du modafinil.
KR970059155A (ko) 트라마돌의 라세미체를 분리하는 방법
CA2494528A1 (en) Racemization and enantiomer separation of clopidogrel
IL169232A (en) Process for preparing duloxetine and intermediates for use therein
HRP20230119T1 (hr) Enantiomerno razdvajanje racemičnog nikotina dodavanjem o,o′-disubstituiranog enantiomera vinske kiseline niske optičke čistoće
KR970021080A (ko) 에난티오머적으로 순수한 이미다졸릴 화합물의 제조방법
WO1998031668A1 (en) Resolution of ritalinic acid salt
PL183204B1 (pl) Sposób racemizacji optycznie wzbogaconej bupiwakainy
RU96120366A (ru) Способ получения энантиомерно чистых соединений имидазолила, энантиомерно чистая кислая аддитивная соль имидазолила и в-пироглутаминовой кислоты
JP4015696B2 (ja) レボブピバカインと同類のピペリジンカルボキサニリド麻酔剤の製造に用いるラセミ化法
JPH10507464A (ja) レボブピバカインとその類似体の晶出
CA2406266A1 (en) A pyridine-1-oxide derivative, and process for its transformation into pharmaceutically effective compounds
WO2001083422A1 (en) Process for the separation of the cis trans diastereoisomers of tramadol
GB0030171D0 (en) Process for preparing isomers of salbutamol
AR030938A1 (es) Proceso de obtencion de los enantiomeros de la cetamina racemica; proceso de obtencion de sales farmaceuticamente aceptables de enantiomeros de la cetamina racemica y utilizacion de las sales farmaceuticamente aceptables obtenidas por el referido proceso
ATE476417T1 (de) Verfahren zur herstellung von carvedilol
Rice et al. Optical resolution of (+-)-2, 5-dimethyl-2'-hydroxy-9. alpha.-and-9. beta.-propyl-6, 7-benzomorphans and their pharmacological properties
WO2008017278B1 (en) Crystalline tolterodine tartarate and a pharmaceutical composition containing the same
Evans et al. Development of highly efficient resolutions of racemic tramadol using mandelic acid
GEP19991791B (en) Pharmacologically Active Enantiomers and Process for its Production
SE8605457D0 (sv) Optically active 2-chloro-12-(3-dimethylamino-2-methylpropyl)-12h-dibenzo(d g)(1,3,6)dioxazocines and a process for the preparation thereof
DE69819479D1 (de) Verfahren zur herstellung eines enantiomers von narwedin

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee